Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Shareholders held by Collegium Pharmaceutical, Inc. on April 25, 2019. The record date for the meeting was March 11, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
A total of 33,371,912 shares were entitled to vote, with 31,329,281 shares present in person or by proxy. The voting outcomes were as follows:
- Proposal 1 (Election of Directors):
- John A. Fallon, M.D.: Elected (17,950,195 For vs. 9,341,907 Against).
- John G. Freund, M.D.: Elected (15,840,746 For vs. 11,451,357 Against).
- David Hirsch, M.D., Ph.D.: Elected (18,159,330 For vs. 9,132,783 Against).
- Joseph Ciaffoni: Elected (27,254,612 For vs. 37,565 Against).
- Proposal 2 (Executive Compensation): Approved on an advisory basis (26,834,464 For vs. 440,040 Against).
- Proposal 3 (Frequency of Compensation Vote): Shareholders voted for an annual advisory vote (27,028,985 for 1 Year).
- Proposal 4 (Auditor Ratification): Deloitte & Touche LLP was ratified (31,292,797 For vs. 29,404 Against).
Guidance, Outlook, and Management Commentary
Following the shareholder vote on Proposal 3, the Board of Directors decided to include an advisory shareholder vote on executive compensation in its proxy materials every year until the next advisory vote on frequency, which will occur no later than the 2025 Annual Meeting. No financial guidance or risk factors were disclosed in this filing.
Important Facts for Investors to Verify
- Significant opposition votes were cast against two Class I director nominees (John A. Fallon and John G. Freund), with "Against" votes exceeding 30% of the total votes cast for those specific nominees.
- Shareholders have mandated annual advisory votes on executive compensation through at least 2025.
- Broker non-votes totaled 4,025,791 shares for Proposals 1, 2, and 3, representing a significant portion of the outstanding shares.